Tests an oral antibiotic to help prevent joint infection after hip or knee replacement
Tests a 7-day antibiotic pill in adults at high risk of joint replacement infection.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Iowa City and Rochester, United StatesSee the 2 sites
- Trial code
- Registry title
- Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 4,618 people, planned
- Started
- 11 Jun 2020
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cephalexin
- Doxycycline
- Cefadroxil
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults planning a first hip or knee replacement who have a higher risk of joint infection. It tests a 7-day course of antibiotic tablets after surgery.
- Age
- 18 to 99 years
- Sex
- All sexes can join.
- Disease stage
- Planned (elective) first total hip or total knee replacement, with at least one infection risk factor: BMI above 35 kg/m^2, diabetes, active smoking, chronic kidney disease, autoimmune disease, or nasal MRSA or MSSA colonization.
- Earlier treatment
- People with a history of Clostridium difficile colitis cannot join. People who cannot take antibiotics by mouth cannot join.
- Biomarker or test result
- Nasal colonization with MRSA or MSSA counts as one of the risk factors.
Main reasons for not taking part
- Cannot take oral antibiotics
- Allergy to the alternative antibiotics in the protocol
- History of Clostridium difficile colitis
- Revision, emergency, hemiarthroplasty or unicompartmental knee surgery
- Pregnant
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient is a candidate for elective, primary total hip arthroplasties (THA) or total knee arthroplasties (TKA)
- Patient is considered high-risk for developing Periprosthetic joint infections (PJI) based on having at least one of the following criteria:
- Body mass index (BMI) > 35 kg/m\^2
- Diagnosis of diabetes mellitus
- Active tobacco smoker
- Chronic kidney disease
- Autoimmune disease
- Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA)
Who cannot take part
- Non-elective surgery
- Allergy to antibiotic alternatives in the protocol
- History of clostridium difficile colitis
- Inability to consume oral antibiotics
- Revision hip or knee arthroplasty procedure
- Hemiarthroplasty
- Unicompartmental knee arthroplasty
- Simultaneous bilateral THA or TKA
- Will have subsequent THA or TKA within 12 weeks of the index study procedure
- Pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- University of Iowa Hospitals & ClinicsIowa City, United StatesEnrolling by invitation
- Mayo ClinicRochester, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
To determine the effectiveness of a 7-day course of an oral, prophylactic antibiotic on the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
The 2 groups in the trial
- Additional Antibiotic GroupExisting treatment, for comparison
Patients will receive an oral antibiotic to be started after completion of standard perioperative antibiotics following primary hip or knee arthroplasty. Oral antibiotic will either be a first-generation cephalosporin (Cefadroxil or Cephalexin) or Doxycycline based upon patient allergies, kidney function and result of nasal colonization testing for MRSA.
Treatment: Cephalexin, Doxycycline, and Cefadroxil
- Control Group - No Additional AntibioticNo study treatment, for comparison
Patients will receive standard perioperative antibiotics following primary hip or knee arthroplasty and no additional antibiotics.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
- Plain-language title
- Tests an oral antibiotic to help prevent joint infection after hip or knee replacementGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04297592, who can take part
- Record updated
- 6 July 2026